Acute ST-elevation myocardial infarction: Management of . . . - UpToDate Patients with acute ST-elevation myocardial infarction (STEMI) should receive coronary reperfusion therapy with either primary percutaneous coronary intervention (PCI) or fibrinolysis For most patients with acute STEMI, we prefer primary PCI rather than fibrinolysis
Thrombolytic Therapy - PubMed This class of medicine is used in acute myocardial infarction, deep vein thrombosis, pulmonary embolism, acute ischemic stroke, acute peripheral arterial occlusion, occlusion of indwelling catheters, and intracardiac thrombus formation
Guidance on the use of drugs for early thrombolysis in the . . . - NICE Acute myocardial infarction (AMI) is caused by blockage of a coronary artery by a thrombus or clot This is usually the result of rupture of an atherosclerotic plaque within the artery The heart muscle supplied by that artery is damaged or dies because of lack of oxygen (ischaemia)
Thrombolysis in Acute Myocardial Infarction | NEJM The use of thrombolytic therapy in patients with acute Q-wave myocardial infarction has resulted in better short-term and medium-term survival and better recovery of left ventricular
Advances in treatments for acute ischemic stroke | The BMJ Acute ischemic stroke is a leading global cause of death and disability Intravenous thrombolysis was the first acute treatment developed for ischemic strokes First with alteplase and now with tenecteplase, intravenous thrombolysis has remained a cornerstone of acute ischemic stroke management In large vessel occlusions, endovascular thrombectomy has become the standard of care in acute
KDIGO GUIDELINES KDIGO has announced its next new guideline will be on Autosomal Dominant Polycystic Kidney Disease (ADPKD) The prevalence of ADPKD worldwide approaches 13 million people This genetic frequently resulting in kidney failure New treatments have emerged in recent years following decades of research
ACC AHA Guidelines for the Management of Patients With Acute Myocardial . . . Patients with myocardial ischemia that is spontaneous or provoked in the days to weeks after acute MI, irrespective of whether they received thrombolytic therapy, ordinarily should undergo elective angiographic evaluation, with subsequent consideration of percutaneous or surgical revascularization
Thrombolysis and Adjunctive Therapy in Acute Myocardial Infarction Acute ST-segment elevation myocardial infarction (MI) is caused by coronary plaque rupture erosion and resultant thrombosis leading to an occluded epicardial infarct-related artery (IRA) 1 2 Timely fibrinolytic therapy can re-establish coronary flow in this setting and salvage jeopardized myocardium
Thrombolytic Therapy in Acute Myocardial Infarction - CHEST Intravenous and intracoronary fibrinolytic therapy in acute myocardial infarction: overview of results on mortality, reinfarction, and side effects from 33 randomized controlled trials
Thrombolytics and myocardial infarction - PubMed In the present era, thrombolytic therapy and primary percutaneous coronary intervention has revolutionized the way patients with acute myocardial infarction are managed resulting in significant reduction in cardiovascular death
Thrombolysis and adjunctive therapy in acute myocardial infarction: the . . . For patients with acute posterior MI of < 12 h duration, we suggest fibrinolytic therapy (Grade 2C) In patients with any history of intracranial hemorrhage, closed head trauma, or ischemic stroke within past 3 months, we recommend against administration of fibrinolytic therapy (Grade 1C+)
Stroke Infarction: Thrombolysis • LITFL • FFS Institutions without this infrastructure should not initiate thrombolysis This guide outlines general principles and does not replace local protocols or specialist consultation Pathophysiology Cerebral infarction results in a central core of dead tissue surrounded by the ischaemic penumbra—partially perfused, potentially salvageable tissue
Acute Non-ST Elevation Myocardial Infarction | Critical Insights Clopidogrel or ticagrelor may also be prescribed for dual antiplatelet therapy 2 Anticoagulants: Medications such as heparin help prevent clot propagation during acute management 3 Beta-blockers: These medications reduce heart rate and myocardial oxygen demand while improving outcomes post-infarction 4
Risk of acute ischemic stroke with early versus late initiation of . . . Cardiogenic shock (CS) remains the most common cause of death in hospitalizations with acute myocardial infarction (AMI) [1, 2] Despite using early revascularization, in-hospital mortality due to AMI complicated by CS (AMI-CS) remains continually high, with rates ranging between 38 and 50% [3,4,5] Supportive medical therapies, such as inotropes, have failed to improve outcomes in this setting